Primaquine
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Using the Evidence Pack as provided (no additional tools needed — this is a direct report-writing task from structured JSON data already supplied). I want to flag one data-quality issue before the report: predicted_indications[0] (myiasis) has zero supporting trials/literature, while several lower-ranked candidates in this same pack (malaria, pneumocystosis, toxoplasmosis) have substantial evidence — and “malaria” is actually Primaquine’s own established indication reappearing as a “prediction.” I followed the template’s literal instruction to use predicted_indications[0] as the headline candidate, but I’ve noted this context in the Conclusion so it isn’t lost.
Primaquine: From Malaria to Myiasis
One-Sentence Summary
Primaquine is a well-established 8-aminoquinoline antimalarial, historically used for the radical cure of Plasmodium vivax and as a gametocytocidal agent against Plasmodium falciparum. The TxGNN model predicts it may be effective for Myiasis, but this specific link is currently supported by 0 clinical trials and 0 publications, making it a purely computational hypothesis at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Malaria (established antimalarial use — radical cure of P. vivax, gametocytocidal against P. falciparum); no India label text available since the drug is not locally registered |
| Predicted New Indication | Myiasis |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L5 (model prediction only, no supporting studies identified) |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Primaquine in this evidence pack (flagged as a High-severity data gap). Based on known pharmacological information corroborated elsewhere in this same pack — the drug’s own “malaria” entry cites 50 clinical trials describing it as “the only drug commercially available that kills mature transmission stage” of P. falciparum and the standard radical-cure agent for P. vivax hypnozoites — Primaquine’s proven efficacy lies squarely in antiprotozoal, blood- and liver-stage antimalarial activity, primarily attributed to oxidative-stress-mediated parasite killing.
Myiasis, in contrast, is a parasitic infestation caused by dipteran fly larvae (not a protozoan), and its established treatments are mechanical larval removal, occlusive therapy, or ivermectin — none of which share Primaquine’s known mechanism. The repurposing rationale field for this specific candidate is marked “pending” with no mechanistic-link data populated, meaning the model’s score is not yet backed by any documented biological hypothesis in this evidence pack.
Given the absence of both a documented mechanistic rationale and any real-world evidence (trials or literature), this candidate should currently be treated as a graph-based signal only — worth flagging for expert review, but not yet supported by pharmacological or clinical reasoning.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
India Market Information
Primaquine currently holds no registrations in the India market data on file (0 licenses; market status: Not Marketed). No product/dosage-form information is available for extraction.
Safety Considerations
Drug Interactions: The evidence pack identifies 278 total documented interactions for Primaquine (source: DDInter). Notable entries include:
| Interacting Drug | Severity Level |
|---|---|
| Dolasetron | Major |
| Famotidine | Moderate |
| Alosetron | Moderate |
| Loperamide | Moderate |
| Clarithromycin | Moderate |
| Levofloxacin | Moderate |
| Ondansetron, Granisetron, Palonosetron | Moderate |
| Metronidazole | Minor |
(20 of 278 total interactions shown; most flagged entries relate to QT-interval-affecting or serotonergic agents, with Dolasetron as the sole Major-level interaction in this sample.)
Separately, literature captured elsewhere in this evidence pack (e.g., PMID 36160421, and multiple malaria/PCP trials such as NCT03337152 and NCT02216123) repeatedly documents hemolytic risk in G6PD-deficient patients as a defining safety concern for Primaquine. This is not part of the structured safety.key_warnings field (which is a blocking data gap in this pack) but is worth flagging as a known class-level risk pending confirmation from official labeling.
Official warning and contraindication text is a blocking data gap in this evidence pack — please refer to the package insert once available for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score for Primaquine → Myiasis is high (99.76%), but there is no corroborating clinical trial, literature, or mechanistic-link evidence in this pack, placing it at Evidence Level L5. Compounding this, the drug-level safety data needed for even a preliminary S1 safety screen (TFDA/label warnings and contraindications) is a Blocking data gap, so this candidate cannot currently advance past S0.
To proceed, the following is needed:
- Official label safety data (warnings/contraindications) to clear the Blocking data gap (DG001)
- Mechanism of action data from DrugBank to support or refute biological plausibility (DG002)
- A targeted literature/trial search specifically for “Primaquine AND myiasis” (or related antiparasitic/larvicidal activity) beyond what this pack currently captures
- Expert (entomology/parasitology) review of biological plausibility, since Primaquine’s known antiprotozoal mechanism has no established link to dipteran larvae
- Consideration of re-scoping this evaluation toward better-evidenced candidates already present in this same pack — notably pneumocystosis (6 trials + 20 publications, including a Phase 3 RCT) and toxoplasmosis (L4, 7 publications) — which have materially stronger evidentiary support than the current rank-1 candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.